BLACK WEEKSFlakoni −15% · komplekti −10% · pārējais −5%ar koduBezmaksas piegāde Vācijā no €200

Šī lapa ir tulkota automātiski un var saturēt kļūdas. Vai latviešu valoda ir jūsu dzimtā valoda? Mēs labprāt saņemsim jūsu atsauksmes un labojumus.Sūtīt atsauksmi

The Peptide Desk The Peptide Desk
RAD-140 (Testolone), produkta foto
SARMs

RAD-140 (Testolone)

SARMs

  • Sūtām no Vācijas

Pasūtījums

Vienības cena - Bezmaksas piegāde Vācijā no 200 € Black Weeks laikā
  • DHL ar izsekošanu
  • Diskrēts iepakojums

4.6 no 5 Trustpilot73 atsauksmes

Meklēts arī kā: Testolon

Īsumā

RAD-140 (Testolone) skaitļos

Galvenie rādītāji no mūsu leksikona. Velciet punktu pa līkni, lai redzētu, cik daudz paliek pēc vienas devas, pēc aprēķina.

Pilns leksikona ieraksts

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~1.9 days

Half-life ~1.9 days
After 3.7 days: 25 %
Day 1, next dose69 %Day 1.949 %Day 3.725 %Day 5.612.4 %Day 9.33.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Half-life

44.7hours

measured in humans

Class
SARMnon-steroidal
Use
Oraldaily
Sizes
10 mg1 size in the shop

Produktam RAD-140 (Testolone) vēl nav laboratorijas analīzes. Balsot par toPasūtiet testu, mēs apmaksājam pusiVisas laboratorijas analīzes

Zināšanas

Viss par RAD-140 (Testolone)

FAQ

Bieži uzdotie jautājumi

Avoti katrai atbildei: leksikona ieraksts

Vēl ir jautājums?

Rakstiet mums, mūsu komanda jums palīdzēs.

How does RAD-140 work?

According to ChEMBL RAD-140 binds to the androgen receptor with a Ki of 7 nM and activated it in muscle cells in the lab. Yu and colleagues found that it activates the receptor in breast cancer cells but not in prostate cancer cells. That is the tissue preference SARMs aim for.

Is RAD-140 approved?

No. On ClinicalTrials.gov there is a single study for RAD140, the completed phase 1 study in breast cancer (as of 26 October 2026). There are no studies in healthy people. Everything here is the state of research, not a recommendation.

What did the phase 1 study show?

22 heavily pretreated women with breast cancer took RAD-140 daily. SHBG fell in all 18 women measured, PSA rose in 16 of 20, a sign of action at the receptor. After 24 weeks 18.2 percent had a benefit, one woman a partial response. Liver values rose often.

What about the liver?

In the phase 1 study AST rose in 59.1 percent, ALT in 45.5 percent. In addition there are case reports. A 26-year-old had acute liver injury, his values normalised two months after stopping. A 24-year-old developed cholestatic liver injury after five weeks of use.

Are there reports on the heart?

Yes, as a case report: Padappayil and colleagues describe a young man with possible acute myocarditis after self-use of RAD-140 for bodybuilding. A case report does not prove a link, but it shows what to watch for.

Is muscle gain proven in humans?

No. The first description by Miller and colleagues shows anabolic effects in animal models. In humans there is only the phase 1 study in women with breast cancer, which did not measure muscle mass.

Salīdzinājumi

Kā tas atšķiras

Saistītie

Saistītie produkti